Speaker Profile
VP & Head of Product., Flatiron Health
Biography
Kate leads the Product teams responsible for evolving our Point of Care and Evidence Solutions product suites in partnership with customers across oncology providers and life sciences, respectively. Since joining Flatiron in 2018, she has launched new products, evolved mature products, and managed teams of various sizes across the organization.Prior to joining Flatiron, Kate worked for Deloitte's Consulting where she led digital transformations in support of life sciences, public health agencies, and transportation industries.Kate received a bachelor's degree in biomedical engineering from the University of Virginia.
Session Abstract – PMWC 2026 Silicon Valley
Track Co-Chairs:
- William Oh, Yale Cancer Center
- David Reese, Amgen
Patient-centric data, such as Real-World Evidence (RWE) and Real-World Data (RWD), has become critical in reshaping drug development and healthcare decision-making. Over the last few years, regulatory agencies like the FDA and EMA have increasingly embraced RWE/RWD for decision-making processes, influencing everything from new drug indications to post-marketing surveillance. The integration of RWE and RWD is not only supporting clinical trial design and regulatory approvals, but also enabling precision medicine by providing deeper insights into patient subpopulations and their outcomes
Sessions:
- TBA
